Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 3/20 | 1.00 |
| ▸ | IKBKB | O14920 | 6/20 | 0.64 |
| ▸ | RAF1 | P04049 | 2/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | AKT1 | P31749 | 2/20 | 0.64 |
| ▸ | AKT2 | P31751 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.64 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.64 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | PRDX1 | Q06830 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122621 | 1.00 | DYRK2 (1.00) | DYRK2IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL29929418 | 1.00 | DYRK2 (1.00) | DYRK2IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL7122623 | 1.00 | DYRK2 (1.00) | DYRK2IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL28833547 | 0.82 | DYRK2 (0.69) | DYRK2IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL11845990 | 0.81 | DYRK2 (0.69) | DYRK2ACHEXDHEGFRPIM1 | |
| SCHEMBL11821606 | 0.81 | DYRK2 (0.69) | DYRK2ACHEXDHEGFRMAPT | |
| SCHEMBL11845989 | 0.81 | DYRK2 (0.69) | DYRK2ACHEXDHEGFRPIM1 | |
| SCHEMBL11821611 | 0.81 | DYRK2 (0.69) | DYRK2ACHEXDHEGFRMAPT | |
| SCHEMBL28096420 | 0.80 | DYRK2 (0.67) | DYRK2IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL29929396 | 0.79 | DYRK2 (0.65) | DYRK2IKBKBRAF1RPS6KB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842705-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842705-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | EMORY UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | EMORY UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-7371766-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371766-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | PGF, VEGFA, VHL | DYRK2 4753/4885IKBKB 178/4885RAF1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.